Literature DB >> 19224794

Xenon preconditioning: the role of prosurvival signaling, mitochondrial permeability transition and bioenergetics in rats.

Yasushi Mio1, Yon Hee Shim, Ebony Richards, Zeljko J Bosnjak, Paul S Pagel, Martin Bienengraeber.   

Abstract

BACKGROUND: Similar to volatile anesthetics, the anesthetic noble gas xenon protects the heart from ischemia/reperfusion injury, but the mechanisms responsible for this phenomenon are not fully understood. We tested the hypothesis that xenon-induced cardioprotection is mediated by prosurvival signaling kinases that target mitochondria.
METHODS: Male Wistar rats instrumented for hemodynamic measurements were subjected to a 30 min left anterior descending coronary artery occlusion and 2 h reperfusion. Rats were randomly assigned to receive 70% nitrogen/30% oxygen (control) or three 5-min cycles of 70% xenon/30% oxygen interspersed with the oxygen/nitrogen mixture administered for 5 min followed by a 15 min memory period. Myocardial infarct size was measured using triphenyltetrazolium staining. Additional hearts from control and xenon-pretreated rats were excised for Western blotting of Akt and glycogen synthase kinase 3 beta (GSK-3beta) phosphorylation and isolation of mitochondria. Mitochondrial oxygen consumption before and after hypoxia/reoxygenation and mitochondrial permeability transition pore opening were determined.
RESULTS: Xenon significantly (P < 0.05) reduced myocardial infarct size compared with control (32 +/- 4 and 59% +/- 4% of the left ventricular area at risk; mean +/- sd) and enhanced phosphorylation of Akt and GSK-3beta. Xenon pretreatment preserved state 3 respiration of isolated mitochondria compared with the results obtained in the absence of the gas. The Ca(2+) concentration required to induce mitochondrial membrane depolarization was larger in the presence compared with the absence of xenon pretreatment (78 +/- 17 and 56 +/- 17 microM, respectively). The phosphoinositol-3-kinase-kinase inhibitor wortmannin blocked the effect of xenon on infarct size and respiration.
CONCLUSIONS: These results indicate that xenon preconditioning reduces myocardial infarct size, phosphorylates Akt, and GSK-3beta, preserves mitochondrial function, and inhibits Ca(2+)-induced mitochondrial permeability transition pore opening. These data suggest that xenon-induced cardioprotection occurs because of activation of prosurvival signaling that targets mitochondria and renders them less vulnerable to ischemia-reperfusion injury.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19224794      PMCID: PMC2748301          DOI: 10.1213/ane.0b013e318192a520

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  39 in total

Review 1.  The phosphoinositide 3-kinase pathway.

Authors:  Lewis C Cantley
Journal:  Science       Date:  2002-05-31       Impact factor: 47.728

2.  Minimum alveolar concentration (MAC) of xenon with sevoflurane in humans.

Authors:  Y Nakata; T Goto; Y Ishiguro; K Terui; H Kawakami; M Santo; Y Niimi; S Morita
Journal:  Anesthesiology       Date:  2001-04       Impact factor: 7.892

3.  Stress-activated protein kinase phosphorylation during cardioprotection in the ischemic myocardium.

Authors:  R M Fryer; H H Patel; A K Hsu; G J Gross
Journal:  Am J Physiol Heart Circ Physiol       Date:  2001-09       Impact factor: 4.733

4.  The direct myocardial effects of xenon in the dog heart in vivo.

Authors:  Benedikt Preckel; Dirk Ebel; Jost Müllenheim; Jan Frässdorf; Volker Thämer; Wolfgang Schlack
Journal:  Anesth Analg       Date:  2002-03       Impact factor: 5.108

5.  Ischemic preconditioning activates phosphatidylinositol-3-kinase upstream of protein kinase C.

Authors:  H Tong; W Chen; C Steenbergen; E Murphy
Journal:  Circ Res       Date:  2000-08-18       Impact factor: 17.367

6.  Xenon does not alter cardiac function or major cation currents in isolated guinea pig hearts or myocytes.

Authors:  D F Stowe; G C Rehmert; W M Kwok; H U Weigt; M Georgieff; Z J Bosnjak
Journal:  Anesthesiology       Date:  2000-02       Impact factor: 7.892

7.  Xenon produces minimal haemodynamic effects in rabbits with chronically compromised left ventricular function.

Authors:  B Preckel; W Schlack; T Heibel; H Rütten
Journal:  Br J Anaesth       Date:  2002-02       Impact factor: 9.166

8.  Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning?

Authors:  Derek J Hausenloy; Helen L Maddock; Gary F Baxter; Derek M Yellon
Journal:  Cardiovasc Res       Date:  2002-08-15       Impact factor: 10.787

9.  Effects of xenon on in vitro and in vivo models of neuronal injury.

Authors:  Stefan Wilhelm; Daqing Ma; Mervyn Maze; Nicholas P Franks
Journal:  Anesthesiology       Date:  2002-06       Impact factor: 7.892

10.  Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B.

Authors:  D A Cross; D R Alessi; P Cohen; M Andjelkovich; B A Hemmings
Journal:  Nature       Date:  1995 Dec 21-28       Impact factor: 49.962

View more
  19 in total

Review 1.  Myocardial AKT: the omnipresent nexus.

Authors:  Mark A Sussman; Mirko Völkers; Kimberlee Fischer; Brandi Bailey; Christopher T Cottage; Shabana Din; Natalie Gude; Daniele Avitabile; Roberto Alvarez; Balaji Sundararaman; Pearl Quijada; Matt Mason; Mathias H Konstandin; Amy Malhowski; Zhaokang Cheng; Mohsin Khan; Michael McGregor
Journal:  Physiol Rev       Date:  2011-07       Impact factor: 37.312

Review 2.  The Role of NMDA Receptors in the Development of Brain Resistance through Pre- and Postconditioning.

Authors:  Leandra Celso Constantino; Carla Inês Tasca; Carina Rodrigues Boeck
Journal:  Aging Dis       Date:  2014-02-12       Impact factor: 6.745

3.  Xenon enhances LPS-induced IL-1β expression in microglia via the extracellular signal-regulated kinase 1/2 pathway.

Authors:  Astrid V Fahlenkamp; Mark Coburn; Hajo Haase; Markus Kipp; Yu-Mi Ryang; Rolf Rossaint; Cordian Beyer
Journal:  J Mol Neurosci       Date:  2010-08-03       Impact factor: 3.444

4.  Isoflurane postconditioning protects against reperfusion injury by preventing mitochondrial permeability transition by an endothelial nitric oxide synthase-dependent mechanism.

Authors:  Zhi-Dong Ge; Danijel Pravdic; Martin Bienengraeber; Phillip F Pratt; John A Auchampach; Garrett J Gross; Judy R Kersten; David C Warltier
Journal:  Anesthesiology       Date:  2010-01       Impact factor: 7.892

Review 5.  Anaesthetics as cardioprotectants: translatability and mechanism.

Authors:  C Kikuchi; S Dosenovic; M Bienengraeber
Journal:  Br J Pharmacol       Date:  2015-01-12       Impact factor: 8.739

Review 6.  Potential therapeutic benefits of strategies directed to mitochondria.

Authors:  Amadou K S Camara; Edward J Lesnefsky; David F Stowe
Journal:  Antioxid Redox Signal       Date:  2010-08-01       Impact factor: 8.401

7.  Therapeutic time window and dose dependence of xenon delivered via echogenic liposomes for neuroprotection in stroke.

Authors:  Tao Peng; George L Britton; Hyunggun Kim; Davide Cattano; Jaroslaw Aronowski; James Grotta; David D McPherson; Shao-Ling Huang
Journal:  CNS Neurosci Ther       Date:  2013-08-24       Impact factor: 5.243

Review 8.  Cellular signaling pathways and molecular mechanisms involving inhalational anesthetics-induced organoprotection.

Authors:  Lingzhi Wu; Hailin Zhao; Tianlong Wang; Chen Pac-Soo; Daqing Ma
Journal:  J Anesth       Date:  2014-03-09       Impact factor: 2.078

9.  Xenon improves neurologic outcome and reduces secondary injury following trauma in an in vivo model of traumatic brain injury.

Authors:  Rita Campos-Pires; Scott P Armstrong; Anne Sebastiani; Clara Luh; Marco Gruss; Konstantin Radyushkin; Tobias Hirnet; Christian Werner; Kristin Engelhard; Nicholas P Franks; Serge C Thal; Robert Dickinson
Journal:  Crit Care Med       Date:  2015-01       Impact factor: 7.598

10.  Xenon preconditioning: molecular mechanisms and biological effects.

Authors:  Wenwu Liu; Ying Liu; Han Chen; Kan Liu; Hengyi Tao; Xuejun Sun
Journal:  Med Gas Res       Date:  2013-01-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.